Comparison of Tacrolimus and Sirolimus Based Regimens on Regulatory T Cell Levels in Renal Transplant Recipients: A Study from a Tertiary Care Centre in Kerala, India

Nasimudeen, Roshan; Francis, Saji; Melemadathil, Sreelatha; Puthenparambath, Sathi

doi:10.7860/jcdr/2019/42355.13190

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Share this opinion; Nasimudeen, et al, concluded that the Immunosuppression with tacrolimus or sirolimus based regimens did not influence the Treg cell levels. The regulatory T cell levels in patients on these regimens were similar to the HCs [33].…”

Section: Discussionmentioning

confidence: 62%

CD62L Percentage in Peripheral T Cells of Kidney Transplant Recipients Children

Rashad¹,

Fadel²,

Salah³

et al. 2021

OJNeph

View full text Add to dashboard Cite

Backgrounds: Recent advances in post Kidney Transplantation (KT) care, have led to a dramatic improvement in short-term outcomes in order to achieve transplantation tolerance; including the ideal tool for clinical monitoring & new therapeutic line. This study was undertaken to analyze the CD62L in Kidney Transplant Recipients (KTRs) and to investigate its efficacy as a marker of good graft survival. Methods: Fifty pediatric KTRs and 12 healthy controls were included in the study, the frequency of T cell activation markers; CD62L was measured with flow cytometry after renal transplantation. Clinical, laboratory, immunosuppressive therapy data and graft function of transplant recipients were collected and correlated with their CD62L peripheral blood percentage. Results: The circulating CD62L% was significantly more in transplant recipients than controls (44.74% ± 17.45% vs. 33.36% ± 11.54%, p = 0.02). CD 62L% was more frequent in recipients of living related donors (p = 0.05), positively correlated with donor age (p = 0.04, r = −0.29*) and CD 4% (p = 0.000, r = 0.615). CD26L% did not show significant association with acute rejection or chronic rejection (p = 0.432, p = 0.91 respectively) or with graft function (serum creatinine or eGFR, p = 0.086, p = 0.988 respectively) or immunosuppressive medications. Conclusion: Peripheral CD62L% is increased after KT than healthy controls, however, it cannot reflect either clinical (serum creatinine and eGFR) or pathological renal graft injury. CD62L surface marker needs more analysis for its potential diagnostic and therapeutic implications as a Treg cell activation marker.

show abstract

Section: Discussionmentioning

confidence: 62%